BPTS

Biophytis S.A. (BPTS) | Rumor.io

Biophytis

BPTS

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about BPTS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Apr 23

$BPTS is undergoing a 1-for-80 reverse stock split, reducing its share float to around 1.1M shares from 92M.
$BPTS is also having a 1-for-40 reverse stock split, reducing ADSs outstanding to around 300,000.
The float for $BPTS is extremely low, resulting in a lack of liquidity.

Generated by AI

Sentiment

Of the messages about BPTS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	100% +18.57
Bearish	0%	0%	0%	0% -18.57

Bullish· Apr 9

$BPTS is launching a Phase 2 clinical study for BIO101 in obesity, which could lead to significant gains.
The stock has a large potential market opportunity, with the obesity treatment market valued at $100 billion.
Biophytis S.A. has shown strong price action, with significant gains and a high float rotation count, indicating high volatility.

Bearish· Sep 25

The asset's price may be artificially held down, leading to potential future losses.
The asset's low float may be a hindrance to its upward movement, contributing to its bearish trend.
The asset is facing significant resistance at $1.4-$1.48, making it a potentially unreliable investment opportunity.

Generated by AI

Topics

Of the messages about BPTS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Announcements· Jul 18

Biophytis S.A. signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's main product.
The partnership aims to produce the active compound for Sarconeos, a drug that treats COVID-19 complications.
Biophytis shares are trading higher after the partnership announcement, with a 60% surge in price.

Technical Analysis· Sep 25

$BPTS has been experiencing a downtrend, with a recent breakout above $1.37.
The stock is facing stiff resistance at $1.4-$1.48, and traders are waiting for it to cross this zone for a safe entry.
$BPTS has been consolidating, and its RSI is oversold, suggesting a potential buying opportunity.

Generated by AI

Community

Of the messages about BPTS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	14.29%
Newcomers	100%	100%	100%	85.71%

Regulars· Apr 9

The stock price of Biophytis S.A. (BPTS) has surged pre-market, increasing by more than 40% after launching its phase 2 clinical study in obesity with BIO101.
Biophytis has launched the OBA phase 2 clinical study in obesity with BIO101, a 20-hydroxyecdysone, which has resulted in a significant stock price increase.
The stock price of BPTS has fluctuated, with a 12.57% drop at $0.402, and a 21.84% drop at $0.4503, in the last few minutes, with increasing trading volume.

Newcomers· Apr 9

Biophytis S.A. (BPTS) shares are trading 41% higher following their earnings, with the company launching a phase 2 clinical study for BIO101 in obesity.
The company's stock has shown significant gains, with a 135% increase in the premarket and a potential bull pennant forming, indicating a possible continuation of the upward trend.
Biophytis S.A. is being considered as a potential "winner" among penny stocks, with some private Discord subscribers claiming to have alerted their members to the stock's potential earlier in the day.

Generated by AI

Also Discussed

Investors talking about BPTS also mention

#	Name	Attention
1	VACC - Vaccitech plc	——
2	ParaZero Technologies Ltd.PRZO	0%+0
3	AWIN - AERWINS Technologies Inc.	——
4	ZVSA - ZyVersa Therapeutics, Inc.	——
5	Femto Technologies Inc.BCAN	0%0
6	SECO - Secoo Holding Limited	——
7	SaverOne 2014 Ltd. ADRSVRE	0%new
8	Earlyworks Co., Ltd. ADRELWS	0%0
9	Wang & Lee Group Inc.WLGS	0%0
10	MINM - Minim, Inc.	——

Biophytis S.A.

Location

Social

What share of all stock conversation is about BPTS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Apr 23

$BPTS is undergoing a 1-for-80 reverse stock split, reducing its share float to around 1.1M shares from 92M.
$BPTS is also having a 1-for-40 reverse stock split, reducing ADSs outstanding to around 300,000.
The float for $BPTS is extremely low, resulting in a lack of liquidity.

Generated by AI

Sentiment

Of the messages about BPTS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	100% +18.57
Bearish	0%	0%	0%	0% -18.57

Bullish· Apr 9

$BPTS is launching a Phase 2 clinical study for BIO101 in obesity, which could lead to significant gains.
The stock has a large potential market opportunity, with the obesity treatment market valued at $100 billion.
Biophytis S.A. has shown strong price action, with significant gains and a high float rotation count, indicating high volatility.

Bearish· Sep 25

The asset's price may be artificially held down, leading to potential future losses.
The asset's low float may be a hindrance to its upward movement, contributing to its bearish trend.
The asset is facing significant resistance at $1.4-$1.48, making it a potentially unreliable investment opportunity.

Generated by AI

Topics

Of the messages about BPTS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Announcements· Jul 18

Biophytis S.A. signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's main product.
The partnership aims to produce the active compound for Sarconeos, a drug that treats COVID-19 complications.
Biophytis shares are trading higher after the partnership announcement, with a 60% surge in price.

Technical Analysis· Sep 25

$BPTS has been experiencing a downtrend, with a recent breakout above $1.37.
The stock is facing stiff resistance at $1.4-$1.48, and traders are waiting for it to cross this zone for a safe entry.
$BPTS has been consolidating, and its RSI is oversold, suggesting a potential buying opportunity.

Generated by AI

Community

Of the messages about BPTS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	14.29%
Newcomers	100%	100%	100%	85.71%

Regulars· Apr 9

The stock price of Biophytis S.A. (BPTS) has surged pre-market, increasing by more than 40% after launching its phase 2 clinical study in obesity with BIO101.
Biophytis has launched the OBA phase 2 clinical study in obesity with BIO101, a 20-hydroxyecdysone, which has resulted in a significant stock price increase.
The stock price of BPTS has fluctuated, with a 12.57% drop at $0.402, and a 21.84% drop at $0.4503, in the last few minutes, with increasing trading volume.

Newcomers· Apr 9

Biophytis S.A. (BPTS) shares are trading 41% higher following their earnings, with the company launching a phase 2 clinical study for BIO101 in obesity.
The company's stock has shown significant gains, with a 135% increase in the premarket and a potential bull pennant forming, indicating a possible continuation of the upward trend.
Biophytis S.A. is being considered as a potential "winner" among penny stocks, with some private Discord subscribers claiming to have alerted their members to the stock's potential earlier in the day.

Generated by AI

Biophytis

Social

Apr 23

Sentiment

Bullish· Apr 9

Bearish· Sep 25

Topics

Announcements· Jul 18

Technical Analysis· Sep 25

Community

Regulars· Apr 9

Newcomers· Apr 9

Also Discussed

Biophytis S.A.

Company Information

Location

Social

Apr 23

Sentiment

Bullish· Apr 9

Bearish· Sep 25

Topics

Announcements· Jul 18

Technical Analysis· Sep 25

Community

Regulars· Apr 9

Newcomers· Apr 9

Also Discussed